Elicera Therapeutics AB ’s Post

What’s in Store for 2024? Three CEOs Look Ahead and Look Back on “Close to the Edge” https://ow.ly/WPPZ50Qmb8E From the approval of Alzheimer’s disease drug Leqembi to Carl Icahn’s battle over Illumina to the first CRISPR-edited therapy being approved, 2023 had more than its share of milestones shaping drug discovery, development, clinical trials, and commercialization. To look back at the year that is ending, and look ahead to 2024, GEN invited CEOs of three companies to offer some valuable perspective on the biopharma industry’s strengths and challenges, and the strengths and challenges of their own companies. • Neil McFarlane, CEO of Zevra Therapeutics • Karen Zaderej, CEO of axogen • Simon Arkell OLY, CEO of Ryght

Thoughts on this? >> Boundless Bio seeks $88M in IPO as it runs two Ph1 cancer trials >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #biotech #pharmaceutical

IRLAB Therapeutics AB In our recent analysis conducted with EQL desktop, we have reviewed IRLAB Therapeutics AB, a biopharmaceutical company based in Gothenburg, Sweden. Current Developments: IRLAB's development pipeline includes Mesdopetam in phase IIb/III trials for dyskinesia in Parkinson’s disease and several preclinical initiatives aimed at neurodegenerative disorders. Strategic Approach: Our research provides an objective look into IRLAB’s strategic methods and the progress of their clinical trials, presenting a clear picture of their operations and potential implications for patient care. Sign up today: https://lnkd.in/dJ8zhDrP #ResearchwithAI #EQL #Irlab #marketintelligence

Thoughts on this? >> Boundless Bio seeks $88M in IPO as it runs two Ph1 cancer trials >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #healthcare #pharma

LucidQuest Strategic Insights (lqventures.com) >>> Gene&Cell Therapy >> Eli Lilly to buy radiopharma company Point Biopharma for $1.4B as PhIII readout looms: On a dealmaking spree, Eli Lilly will buy another cancer biotech, this time swooping in for publicly traded radiopharma company Point Biopharma in a cash acquisition worth about $1.4 billion. Lilly’s addition of a radiopharmaceutical company comes as the space heats up with new startups, a recent IPO from RayzeBio and high demand for Novartis’ Pluvicto. The Big Pharma is moving in on Point as it anticipates late-stage clinical data in the near term, with two radioligand cancer therapies in Phase III development. The deal, disclosed Tuesday pre-market for $12.50 per share, marks at least the fifth acquisition for Lilly in as many months as it receives a financial and stock boost from the performance of its diabetes drug Mounjaro, which is also being prescribed off-label for weight loss, and its much-anticipated Alzheimer’s drug donanemab. In recent months, the Indianapolis Big Pharma has bought autoimmune biotech DICE Therapeutics, weight loss drugmaker Versanis, diabetes cell therapy company Sigilon and antibody-drug conjugate startup Emergence Therapeutics. For Point, the tender offer marks a 68% premium to its 30-day volume-weighted average price. The deal is expected to close “near the end of 2023” and has already been greenlit by both boards, the companies said. Point’s shares $PNT skyrocketed 84% before Tuesday’s opening bell, nearly reaching the tender offer price of $12.50 apiece. Point’s lead program is PNT2002, a PSMA-targeted radioligand therapy that will have topline data this quarter for patients with metastatic castration-resistant prostate cancer after progression on hormonal treatment. Point is also developing an SSTR-targeted radioligand therapy, PNT2003, for patients with gastroenteropancreatic neuroendocrine tumors. Novartis’ radioligand therapy Lutathera hit the mark in a Phase III in that population last month, and RayzeBio is currently enrolling for its Phase III. Jacob Van Naarden “We are excited by the potential of this emerging modality and see the acquisition of Point as the beginning of our investment in developing multiple meaningful radioligand medicines for hard-to-treat cancers, as we have done in small molecule and biologic oncology drug discovery and development,” Jacob Van Naarden, president of Lilly’s oncology unit Loxo@Lilly, said in a statement. Point is also based in Indianapolis. It went public in July 2021 via an RA Capital-sponsored SPAC known as Research Alliance Corp. I. Notably, Lilly chief scientific officer Dan Skovronsky moved his way up the Big Pharma’s ladder after the drugmaker bought his radiopharma company, Avid Radiopharmaceuticals, in 2010. Editor’s note: This story was updated to include Point’s stock… #lucidquest #genetherapy #celltherapy

I'm pleased to announce the addition of Jeeshan Chowdhury, MD, Ph.D., Chief Executive Officer & Co-Founder, Journey Colab to the agenda for the 4th Annual Psychedelic Therapeutics Conference, taking place in Boston on May 23-24, 2024. He will be discussing the issue of fundraising for psychedelic drug programs. In the ever-evolving landscape of drug development, securing later-stage funding remains a critical bottleneck, especially in the burgeoning field of psychedelic medicine. One of the key challenges currently facing drug development companies is navigating the complex path from research to commercialization. This session aims to introduce a groundbreaking approach to address this challenge. This session will be of particular interest to drug developers grappling with commercialization challenges. This approach is uniquely positioned to not only advance the clinical science but also to build a strategy for commercialization, thereby addressing the most pressing issue in the psychedelic industry today. Learn more about this event by visiting https://lnkd.in/eM5iiPn. #psychedelics #psychedelicresearch #psychedelictherapy #boston

Developing next-generation complement therapeutics requires a deep understanding of the complement system. Join our on-demand roundtable featuring academia and industry experts who will share their knowledge and insights on this important topic. Register to watch now and learn from experts in the complement field! https://hubs.ly/Q01WRqKW0

Source. Plan. Invest. Execute. These sound like simple directions, but in the context of pre-seed therapeutics investment the route can be hard to navigate. In the next chapter of Evotec’s White Paper series, ‘From academic concept to commercial reality: How to accelerate translational drug discovery’ we take a look from an investor’s perspective at the way-markers for a successful translational roadmap. Read chapter 2, 'Source. Plan. Invest. Execute. Navigating the tough roadmap of pre-seed therapeutics investment' here - https://hubs.ly/Q02j-Bfx0 #researchneverstops

Are you attending the Complement-Based Drug Development Summit in Boston? Tomorrow, on Tuesday, 9/12, at 12:00 (EDT), don't miss Dr. Michael Schwenkert, Chief Product & Technology Officer (https://hubs.ly/Q020Nhvy0) as he presents "The Complement System in Drug Development – step-by-step towards the Bigger Picture." His presentation will highlight: • Quantitative biomarker evaluation • Functional anaphylatoxin detection • Assessment of pathway and convertase activity Interested in learning more about us? Visit our booth to meet our team of experts, ready to answer your questions and provide valuable insights into the challenges of developing next-generation therapeutics. #svarlifescience #answersinlifescience #expertpartner #partnerwithus #complementterapeuthics #complement #complementsystem #complementinglifescience"